Class action filed against GeneDx for alleged securities fraud affecting investors from 2025-2026.

A class action lawsuit has been filed against GeneDx Holdings Corp. and some of its officers for allegedly misleading investors between April 16, 2025, and May 4, 2026. The complaint claims the company made false statements and failed to disclose key negative facts about its business, including issues with Fabric Genomics, declining margins, and less durable reimbursement rates. Investors who bought GeneDx securities during this period are encouraged to join the lawsuit, with a lead plaintiff deadline of August 3, 2026. The law firm Bronstein, Gewirtz & Grossman, LLC is representing affected investors on a contingency fee basis, meaning no upfront cost unless they win.